BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 16860174)

  • 1. Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials.
    Rowan JP; Simon JA; Speroff L; Ellman H
    Clin Ther; 2006 Jun; 28(6):921-32. PubMed ID: 16860174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt) on the frequency and intensity of vasomotor symptoms.
    Speroff L; Symons J; Kempfert N; Rowan J;
    Menopause; 2000; 7(6):383-90. PubMed ID: 11127760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women.
    Phillips TJ; Symons J; Menon S;
    J Am Acad Dermatol; 2008 Sep; 59(3):397-404.e3. PubMed ID: 18625536
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial.
    Speroff L; Rowan J; Symons J; Genant H; Wilborn W
    JAMA; 1996 Nov; 276(17):1397-403. PubMed ID: 8892714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators.
    Symons J; Kempfert N; Speroff L
    Obstet Gynecol; 2000 Sep; 96(3):366-72. PubMed ID: 10960627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy.
    Simon JA; Liu JH; Speroff L; Shumel BS; Symons JP
    Am J Obstet Gynecol; 2003 Jan; 188(1):92-9. PubMed ID: 12548201
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens.
    Simon JA; Symons JP;
    Menopause; 2001; 8(5):321-7. PubMed ID: 11528357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects.
    Greenwald MW; Gluck OS; Lang E; Rakov V
    Menopause; 2005; 12(6):741-8. PubMed ID: 16278618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women.
    Samsioe G; Dvorak V; Genazzani AR; Hamann B; Heikkinen J; Mueck AO; Suzin J; Kawakami FT; Ferreira A; Sun D; Arguinzoniz M
    Maturitas; 2007 Jun; 57(2):171-81. PubMed ID: 17317046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause.
    Notelovitz M; Cassel D; Hille D; Furst KW; Dain MP; VandePol C; Skarinsky D
    Am J Obstet Gynecol; 2000 Jan; 182(1 Pt 1):7-12. PubMed ID: 10649149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term and long-term effects of tibolone in postmenopausal women.
    Formoso G; Perrone E; Maltoni S; Balduzzi S; Wilkinson J; Basevi V; Marata AM; Magrini N; D'Amico R; Bassi C; Maestri E
    Cochrane Database Syst Rev; 2016 Oct; 10(10):CD008536. PubMed ID: 27733017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement.
    Williams SR; Frenchek B; Speroff T; Speroff L
    Am J Obstet Gynecol; 1990 Feb; 162(2):438-46. PubMed ID: 2309827
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioidentical hormones for women with vasomotor symptoms.
    Gaudard AM; Silva de Souza S; Puga ME; Marjoribanks J; da Silva EM; Torloni MR
    Cochrane Database Syst Rev; 2016 Aug; 2016(8):CD010407. PubMed ID: 27479272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study.
    Duvernoy CS; Rose PA; Kim HM; Kehrer C; Brook RD
    J Womens Health (Larchmt); 2007 Sep; 16(7):963-70. PubMed ID: 17903073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials.
    Shulman LP; Yankov V; Uhl K
    Menopause; 2002; 9(3):195-207. PubMed ID: 11973443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of combined oral estrogen/progestogen preparation (Kliogest) on bone mineral density, plasma lipids and postmenopausal symptoms in HRT-naïve Thai women.
    Jirapinyo M; Theppisai U; Manonai J; Suchartwatnachai C; Jorgensen LN
    Acta Obstet Gynecol Scand; 2003 Sep; 82(9):857-66. PubMed ID: 12911449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone.
    Portman DJ; Symons JP; Wilborn W; Kempfert NJ
    Am J Obstet Gynecol; 2003 Feb; 188(2):334-42. PubMed ID: 12592236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life.
    Soares CN; Arsenio H; Joffe H; Bankier B; Cassano P; Petrillo LF; Cohen LS
    Menopause; 2006; 13(5):780-6. PubMed ID: 16894334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation the efficacy and safety of estradiol and drospirenone tablets in the treatment of menopausal symptoms among postmenopausal Chinese healthy women:a randomized, multi-center, double-blind, placebo-controlled clinical study].
    Zhou YZ; Sun LZ; Lin JF; Yang X; Zhang LJ; Qiao J; Wang ZH; Xu YX; Xiong ZA; Lin SQ
    Zhonghua Fu Chan Ke Za Zhi; 2011 May; 46(5):345-9. PubMed ID: 21733370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cost-effectiveness evaluation of two continuous-combined hormone therapies for the management of moderate-to-severe vasomotor symptoms.
    Botteman MF; Shah NP; Lian J; Pashos CL; Simon JA
    Menopause; 2004; 11(3):343-55. PubMed ID: 15167315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.